Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin

TY - JOUR

T1 - Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin

AU - Nanna, Michael G.

AU - Navar, Ann Marie

AU - Giugliano, Robert P.

AU - White, Jennifer A.

AU - Lokhnygina, Yuliya

AU - Mitchel, Yale B.

AU - Musliner, Thomas A.

AU - Cannon, Christopher P.

AU - Blazing, Michael A.

N1 - Funding Information: Please note: The IMPROVE-IT trial was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck. Dr. Nanna is supported by the National Institutes of Health training grant T-32-HL069749-15. Dr. Navar is funded by National Institutes of Health grant K01HL133416-01; has received research grants (significant) from Amarin, Janssen, Amgen, Sanofi, and Regeneron Pharmaceuticals; and has served as a consultant/advisory board member (significant) for Amarin, Amgen, Novo Nordisk, AstraZeneca, Sanofi, and Regeneron. Dr. Giugliano has received grants from Merck to his institution during the conduct of the study; has received personal fees from Akcea, Amarin, the American College of Cardiology, Angel Med, Beckman-Coulter, Boehringer Ingelheim, Bristol-Myers Squibb, CVS Caremark, GlaxoSmithKline, Janssen, Lexicon, Portola, Pfizer, St. Jude, and Stealth Peptide; has received grants and personal fees from Amgen, Daiichi-Sankyo, and Merck outside of the submitted work; and has received an institutional research grant to the TIMI Study Group at Brigham and Women's Hospital for research he is not directly involved in from AstraZeneca, Bayer, Eisai, GlaxoSmithKline, Intarcia, Janssen Research and Development, The Medicines Company, MedImmune, Novartis, Poxel, Pfizer, Quark Pharmaceuticals, and Takeda. Dr. Mitchel is an employee of Merck Sharp & Dohme, a subsidiary of Merck. Dr. Musliner is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck; and owns stock in Merck. Dr. Cannon has received research grants (all >$10,000) from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, Merck, and Pfizer; and has received consulting fees from Aegerion, Alnylam, Amarin, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Corvidia, Eisai, Innovent, Janssen, Kowa, Merck, Pfizer, Regeneron, and Sanofi (Sanofi >$10,000). Dr. Blazing has received research support from Merck; has received consulting fees from Espirion (<$10,000); and has received indirect support from Sanofi through Duke Clinical Research Institute 3 years ago. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors thank Dr. Eugene Braunwald for his important contributions to this manuscript, and Elizabeth Cook for her editorial contributions. Ms. Cook did not receive compensation for her contributions, apart from her employment at the institution where this study was conducted. (IMPROVE-IT [Improved Reduction of Outcomes: Vytorin Efficacy International Trial]; NCT00202878) Funding Information: Please note: The IMPROVE-IT trial was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck. Dr. Nanna is supported by the National Institutes of Health training grant T-32-HL069749-15. Dr. Navar is funded by National Institutes of Health grant K01HL133416-01; has received research grants (significant) from Amarin, Janssen, Amgen, Sanofi, and Regeneron Pharmaceuticals; and has served as a consultant/advisory board member (significant) for Amarin, Amgen, Novo Nordisk, AstraZeneca, Sanofi, and Regeneron. Dr. Giugliano has received grants from Merck to his institution during the conduct of the study; has received personal fees from Akcea, Amarin, the American College of Cardiology, Angel Med, Beckman-Coulter, Boehringer Ingelheim, Bristol-Myers Squibb, CVS Caremark, GlaxoSmithKline, Janssen, Lexicon, Portola, Pfizer, St. Jude, and Stealth Peptide; has received grants and personal fees from Amgen, Daiichi-Sankyo, and Merck outside of the submitted work; and has received an institutional research grant to the TIMI Study Group at Brigham and Women's Hospital for research he is not directly involved in from AstraZeneca, Bayer, Eisai, GlaxoSmithKline, Intarcia, Janssen Research and Development, The Medicines Company, MedImmune, Novartis, Poxel, Pfizer, Quark Pharmaceuticals, and Takeda. Dr. Mitchel is an employee of Merck Sharp & Dohme, a subsidiary of Merck. Dr. Musliner is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck; and owns stock in Merck. Dr. Cannon has received research grants (all >$10,000) from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, Merck, and Pfizer; and has received consulting fees from Aegerion, Alnylam, Amarin, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Corvidia, Eisai, Innovent, Janssen, Kowa, Merck, Pfizer, Regeneron, and Sanofi (Sanofi >$10,000). Dr. Blazing has received research support from Merck; has received consulting fees from Espirion (<$10,000); and has received indirect support from Sanofi through Duke Clinical Research Institute 3 years ago. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors thank Dr. Eugene Braunwald for his important contributions to this manuscript, and Elizabeth Cook for her editorial contributions. Ms. Cook did not receive compensation for her contributions, apart from her employment at the institution where this study was conducted. (IMPROVE-IT [Improved Reduction of Outcomes: Vytorin Efficacy International Trial]; NCT00202878 )

PY - 2020/2/25

Y1 - 2020/2/25

UR - http://www.scopus.com/inward/record.url?scp=85079161591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079161591&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2019.12.022

DO - 10.1016/j.jacc.2019.12.022

M3 - Letter

C2 - 32081289

AN - SCOPUS:85079161591

SN - 0735-1097

VL - 75

SP - 835

EP - 837

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 7

ER -